NAPHAZOLINE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NAPHAZOLINE HYDROCHLORIDE (NAPHAZOLINE HYDROCHLORIDE).
Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.
| Metabolism | Not extensively studied; likely hepatic metabolism via unknown enzymes. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; exact % not established in humans due to limited systemic absorption after topical use. In animal studies, ~30-40% excreted unchanged in urine. |
| Half-life | Approximately 2-3 hours after systemic absorption; clinical effect is limited by local vasoconstriction rather than plasma half-life. |
| Protein binding | Not well characterized; expected to be low (<20%) based on structural analogs. |
| Volume of Distribution | Not established in humans; based on animal data, approximately 0.5-1.0 L/kg, suggesting distribution into total body water. |
| Bioavailability | Ophthalmic and intranasal: low systemic bioavailability due to local vasoconstriction limiting absorption; exact % not determined, estimated <1%. |
| Onset of Action | Ophthalmic: within 10 minutes; Intranasal: within 5-10 minutes. |
| Duration of Action | Ophthalmic: 2-6 hours (shorter with repeated use due to tachyphylaxis); Intranasal: 2-6 hours (rebound congestion with prolonged use). |
1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required; primarily locally acting with minimal systemic absorption. |
| Liver impairment | No dose adjustment required; use caution in severe hepatic impairment due to potential for systemic effects. |
| Pediatric use | Children ≥6 years: 1-2 drops of 0.1% ophthalmic solution every 6-8 hours; nasal spray 0.05% for children ≥6 years, 1 spray per nostril every 8-10 hours. Contraindicated in infants and children <6 years due to risk of CNS depression. |
| Geriatric use | Elderly patients may be more sensitive to adverse effects (e.g., rebound congestion, hypertension); use lowest effective dose and shortest duration. Avoid in patients with cardiovascular disease or glaucoma. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NAPHAZOLINE HYDROCHLORIDE (NAPHAZOLINE HYDROCHLORIDE).
| Breastfeeding | Excretion in human milk is unknown. Due to low systemic absorption after topical application, amounts ingested by an infant are expected to be minimal. No known adverse effects in nursing infants. M/P ratio not reported. Consider benefit of treatment versus potential risk to infant. Use caution and avoid prolonged or excessive dosing. |
| Teratogenic Risk | Naphazoline hydrochloride is an alpha-adrenergic agonist used as a topical decongestant. Systemic absorption is minimal with topical ocular or nasal use; however, theoretical risks include vasoconstriction and reduced uterine blood flow. No adequate and well-controlled studies in pregnant women. Animal studies have not been reported. First trimester: No known teratogenic effects. Second and third trimesters: Potential risk of reduced uteroplacental perfusion when used systemically; topical use at recommended doses unlikely to cause significant effects. Overall, classified as FDA Pregnancy Category C. Caution is advised. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to naphazoline or any component. Narrow-angle glaucoma (ophthalmic use). Use with MAO inhibitors or within 14 days of stopping therapy (risk of hypertensive crisis).
| Precautions | Prolonged use may cause rebound congestion (rhinitis medicamentosa). Use with caution in patients with cardiovascular disease (hypertension, arrhythmias), hyperthyroidism, diabetes, or prostatic hyperplasia. Avoid use in patients with narrow-angle glaucoma. Do not exceed recommended dosage or duration. |
Loading safety data…
| Fetal Monitoring | No specific clinical monitoring required for topical use at recommended doses. Monitor for maternal hypertension, tachycardia, or other systemic effects with excessive use. Fetal monitoring only if signs of maternal toxicity or reduced uterine perfusion are suspected. |
| Fertility Effects | No known effects on fertility in humans. Animal reproductive studies have not been conducted. Minimal systemic absorption suggests unlikely impact on reproductive function at recommended topical doses. |